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1162Objective: To investigate whether the use of miniaturized cardiopulmonary bypass translates into decreasedmor-
bidity and mortality in patients having cardiac surgery.
Methods:We independently conducted a systematic review and meta-analysis of data pooled from existing trials
listed in PubMed and conference proceedings. Sixteen studies were identified, including 1619 patients having
cardiac surgery. Inclusion criteria were random allocation to treatment and comparison of a miniaturized cardio-
pulmonary bypass system versus conventional cardiac surgery. Exclusion criteria were duplicate publications,
nonhuman experimental studies, and no outcome data. The end points were the rate of neurologic and myocardial
damage and the number of patients transfused.
Results:Miniaturized cardiopulmonary bypass was associated with significant reductions of neurologic damage
(4/548 [0.7%] vs 19/555 [3.4%], odds ratio ¼ 0.30 [0.12–0.73], P ¼ .008), reduction in peak cardiac troponin
(weighted mean difference ¼ –0.15 ng/dL [0.18,0.11], P< .001), and in the number of transfused patients
(55/552 [9.9%] vs 101/563 [17.9%], odds ratio ¼ 0.42 [0.28–0.63], P< .001). No difference in mortality
was noted (8/758 [1.0%] vs 14/771 [1.8%], odds ratio ¼ 0.60 [0.26–1.39]).
Conclusions:Miniaturized cardiopulmonary bypass has beneficial effects resulting in decreased transfusion rate
and cardiac and neurologic damage. (J Thorac Cardiovasc Surg 2010;139:1162-9)Cardiopulmonary bypass (CPB) with aortic crossclamping
and cardioplegic arrest remains the gold standard technique
to perform cardiac surgery. It induces an inflammatory re-
sponse (largely determined by the blood contact with foreign
surface and the activation of the complement) and renal, pul-
monary, and neurologic dysfunction.1,2 Coronary artery by-
pass grafting (CABG) using CPB is still the most accepted
technique to treat coronary artery disease. However, the
morbidity attributed to CPB is still significant.3
The search for a less aggressive and more biocompatible
CPB led to the use of miniaturized CPB, based on the idea
of a closed low prime volume circuit consisting of a rotary
blood pump and a membrane oxygenator as the only compo-
nents. The venous blood returns through active drainage.
There is no venous reservoir and no cardiotomy suction de-
vice. Itminimizes hemodilutionandmechanical blood trauma.
The shed blood is separated from the systemic circulation. The
components, including the tubing, are heparin-coated.4,5e Department of Anesthesia and Intensive Care,a Universita` Vita-Salute San
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The Journal of Thoracic and Cardiovascular SurTo address the question whether the use of miniaturized
CPB might influence patients’ outcome after cardiac sur-
gery, we independently conducted a systematic review and
meta-analysis of data pooled from existing trials to deter-
mine the impact of miniaturized CPB on the rate of transfu-
sion and on cardiac and neurologic damage in patients
having cardiac surgery.
MATERIALS AND METHODS
Search Strategy
Pertinent studies were independently searched in PubMed (updated May
20, 2008) by 4 trained investigators. The full PubMed search strategy was
developed according to Biondi-Zoccai and colleagies6 and is available in
the appendix. Further hand or computerized searches involved the recent
(2006–2008) conference proceedings from the International Anesthesia Re-
search Society, European Association of Cardiothoracic Anaethesiologists,
and European Association of Cardiothoracic Surgery congresses. In addi-
tion, we used backward snowballing (ie, scanning of references of retrieved
articles and pertinent reviews) and contacted international experts for further
studies. No language restriction was enforced and non–English-language ar-
ticles were translated before further analysis. In the present study, miniatur-
ized CPB was defined as a system with a low prime circuit and without
a cardiotomy reservoir, in which venting lines are driven into the cell saver
directly or into a vacuum bag reservoir. No blood–air contact was com-
pounded in this system; shed blood separation was strictly followed. Con-
ventional CPB was defined as what is routinely used in every routine
cardiac surgery procedure: massive hemodilution, cardiotomy suction,
blood–air contact.
Study Selection
References obtained from database and literature searches were first in-
dependently examined at the title/abstract level by 4 investigators withgery c May 2010
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tients 1619: MECCcoronary artery bypass graftingCPB ¼ cardiopulmonary bypass
OR ¼ odds ratio
QUOROM ¼ The Cochrane Collaboration and
the Quality of Reporting of
Meta-AnalysesWMD ¼ weighted mean differencesdivergences resolved by consensus, and then, if potentially pertinent, re-
trieved as complete articles.
The following inclusion criteria were employed for potentially relevant
studies: random allocation to treatment and comparison of a miniaturized
CPB system versus a conventional cardiac surgery. Exclusion criteria
were duplicate publications (in this case only the article reporting the lon-
gest follow-up was abstracted), nonhuman experimental studies, and lack
of outcome data.
Two investigators independently assessed compliance to selection crite-
ria and selected studies for the final analysis, with divergences finally re-
solved by consensus (Table 1).
Data Abstraction and Study Characteristics
Baseline, procedural, and outcome data were independently abstracted
by 4 trained investigators with divergences resolved by consensus (Table
1, Table 2). Specifically, we extracted study end points and main outcomes,rnals, year of publication, miniaturized CPB device
eta-analysis
Journal Year
Min
Thorac Surg 2005 CorX system
Thorac Surg 2006 Jostra MECC
Clara, Cal
Thorac Surg 2007 Maquet Card
Germany)
J Cardiothorac Surg 2002 Jostra MECC
Germany)
Thorac Surg 2007 Synergy min
Germany)
ract Cardiovasc Thorac Surg 2006 Resting Hear
Mirandola
ract Cardiovasc Thorac Surg 2007 Nonspecified
culation 2007 Jostra MECC
rtif Organs 2007 Capiox, Teru
fusion 2007 Jostra MECC
horac Cardiovasc Surg 2004 Jostra MECC
Clara, Cal
Heart J 2006 Jostra MECC
horac Cardiovasc Surg 2008 Maquet Card
Germany)
IO J 2007 Maquet Card
Minneapo
nd Cardiovasc J 2007 Extra-Corpor
Germany)
J Cardiothorac Surg 2005 CorX system
803, control 816. CPB, Cardiopulmonary bypass; Mini CPB, m
The Journal of Thoracic and Carstudy design (including patient selection, randomization, single-/multicen-
ter design, open or single-/double-blind design), clinical setting, population,
and adverse events.
The primary end point of the present review was the rate of blood trans-
fusion and cardiac and neurologic outcome, and the coprimary end point
was the rate of hospital mortality. Blood transfusionwas defined as the num-
ber of patients receiving at least 1 U of red blood cells during surgery or in
the postoperative period. Cardiac damage was defined as an increase of the
cardiac biomarker cardiac troponin I. Neurologic damage was defined as
postoperative type 1 (focal neurologic complication) or type 2 (altered men-
tal status) neurologic complication.
Other relevant secondary end points were time on mechanical ventila-
tion, intensive care unit and hospital stay, atrial fibrillation, bleeding
(mL), surgical reexploration, myocardial infarction, intra-aortic balloon,
low cardiac output syndrome, use of inotropic drugs. At least 2 separate at-
tempts at contacting original authors were made in cases of missing data.
Internal Validity and Risk of Bias Assessment
The internal validity and risk of bias of included trials were appraised ac-
cording to revised methods recommended by The Cochrane Collaboration
methods (Table 3). Two independent reviewers appraised study quality,
with divergences resolved by consensus.
Data Analysis and Synthesis
Computations were performed with SPSS 11.0 (SPSS, Chicago, Ill) and
RevMan 4.2 (a freeware available from The Cochrane Collaboration).7 Sta-
tistical heterogeneity and inconsistency was measured using, respectively,
Cochran Q tests and I2. Binary outcomes from individual studies were an-
alyzed to compute individual and pooled odds ratios (ORs) with pertinentused, and number of patients included in the 16 randomized controlled
i CPB device manufacturer
and location Patients
MECC
patients
Control
patients
(Jostra AG, Hirrlingen, Germany) 204 101 103
system (CardioVention Inc, Santa
if)
60 30 30
iopulmonary (Jostra AG, Hirrlingen, 40 17 23
system (Jostra AG, Hirrlingen, 60 30 30
i-bypass system (Cobe) (Rastatt, 49 25 24
t System (RHS) (Dideco SrL,
, Italy)
20 10 10
(Jostra, France) 150 75 75
system (Tokyo, Japan) 306 150 156
mo (Jostra Inc, Hirrlingen, Germany) 30 15 15
system (nonspecified) 20 10 10
system (CardioVention Inc, Santa
if)
100 50 50
system (Dideco, Mirandola, Italy) 400 200 200
iopulmonary (Jostra AG, Hirrlingen, 60 30 30
iopulmonary (Medtronic, Inc,
lis, Minn)
60 30 30
eal Circulation Optimized (Hirrlingen, 40 20 20
(nonspecified) 20 10 10
iniaturized cardiopulmonary bypass.
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TABLE 2. Details of interventions and of CPB characteristics in miniaturized cardiopulmonary bypass (mini CPB) or in controls in the 16
randomized controlled trials included in this meta-analysis
First author
Cardiac
surgery
procedures
Priming,
mini
CPB
(mL)
Priming,
control
(mL)
Circuits,
mini
CPB
Circuits,
control
ACT,
mini
CPB (s)
ACT,
control
(s)
Total
heparin
dose,
mini CPB
Total
heparin
dose,
control
Abdel-
Rahman U
CABG 500 1750 Heparin-coated Membrane
oxygenator-coated
>400 >400 5000 IUþ
350 IU/kg
10000 IUþ
350 IU/kg
Beghi C CABG 450 1500 Heparin-coated Noncoated nr nr 150 IU/kg 300 IU/kg
Castiglioni A Aortic valve
replacement
500 1600 Heparin-coated Coated with
phosphorylcholine
>480 >480 300 IU/kg 5000 UIþ
300 IU/kg
Fromes Y CABG 500 nr Heparin-coated Heparin-coated nr nr 300 UI/kg 300 UI/kg
Huybregts RA CABG 600 1400 Phosphorylcholine-
coated
Coated with
phosphorylcholine
480 s 480 s 400 IU/kg 400 IU/kg
Kamiya H CABG 900 1540 Heparin-coated Heparin-coated >400 >400 150 U/kg 300 U/kg
Kutschka I Aortic valve and
aortic root surgery
nr nr nr nr nr nr nr nr
Mazzei V CABG No No nr No nr nr nr nr
Ohata T CABG 750 nr Heparin-coated Heparin-coated nr nr 300 U/kg 300 U/kg
Prasser C CABG 550 1500 Heparin-coated Heparin-coated 250–300 >400 150 IU/kg 375 IU/kg
Remadi JP Aortic valve
replacement
450 1700 Heparin-coated Noncoated >400 >400 150 IU/kg 300 IU/kg
Remadi JP CABG 450 1700 Heparin-coated Noncoated 400 400 300 IU/kg 300 IU/kg
Scho¨ttler J CABG 900 1700 Heparin-coated Heparin-coated nr nr 5000 IUþnr 10000 IUþnr
Skrabal CA CABG 500 1500 Heparin-coated Heparin-coated 250 400 200–350
IU/kg
200–350
IU/kg
Valtonen M CABG 380 2100 Phosphorylcholine-
coated
Phosphorylcholine-
coated
480 480 300 IU/kg 300 IU/kg
Wippermann J CABG 820 1750 Phosphorylcholine-
coated
Phosphorylcholine-
coated
450 nr 400 IU/kg 400 IU/kg
ACT, Activated clotting time; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; nr, not reported.
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D95% confidence intervals (with equivalence set at 1, OR<1 favoring the first
treatment, and OR>1 favoring the second treatment), by means of the Peto
fixed-effect method in case of low statistical inconsistency (I225%) and
by means of a random-effect method (which better accommodates clinical
and statistical variations) in case of moderate or high statistical inconsis-
tency (I2>25%). Weighted mean differences (WMD) and 95% confidence
intervals were computed for continuous variables, again by means of
a fixed-effect method in case of low statistical inconsistency (I225%)
and by means of a random-effect method in case of moderate or high statis-
tical inconsistency (I2>25%).7
The risk of small-study bias (including publication bias, ie, the risk of
small, nonsignificant studies being selectively rejected by medical journals)
was assessed by visual inspection of funnel plots.
Statistical significance was set at the 2-tailed .05 level for hypothesis test-
ing and at .10 for heterogeneity testing, and unadjusted P values are reported
throughout. This study was performed in compliance with The Cochrane
Collaboration and the Quality of Reporting of Meta-Analyses (QUOROM)
guidelines.8,9
RESULTS
Database searches, snowballing, and contacts with ex-
perts yielded a total of 629 citations (Figure 1). Excluding
607 nonpertinent titles or abstracts, we retrieved 22 studies
in complete form and assessed them according to the selec-
tion criteria. A total of 6 studies were further excluded be-
cause of their nonexperimental design, including the use
of historical controls, or because of duplicate publication.1164 The Journal of Thoracic and Cardiovascular SurSpecifically, we excluded 3 studies because of duplicate
publication either explicitly acknowledged10 or not11,12: 2
studies13,14 because there were no outcome data and further
details could not be obtained by the authors and 1 non-
randomized trial.15
We finally identified 16 eligible randomized clinical tri-
als,16-31 which were included in the final analysis (Table 1).
Study Characteristics
The 16 included trials randomized 1619 patients (803 to
miniaturized CPB and 816 undergoing standard cardiac
surgery; Table 1). Most studies were performed on patients
undergoing on-pump CABG, 1 studied patients having off-
pump CABG,23 and 2 investigated patients having aortic
valve replacement.18,26 No patients having cardiac reinter-
vention were included. Most authors used the Jostra
MECC System. No study was multicentric. In all the studies,
cardioplegia was identical in the 2 groups with the exception
of the study with the off-pump comparator group and of the
only study that was published as an abstract only,22 where
there was no detail about cardioplegia. All patients were
managed with normothermia or mild hypothermia equally
in the 2 groups. No cardiotomy suction was used. Details
on the 2 study groups are reported in Table 2.gery c May 2010
TABLE 3. Risk of bias assessment of included studies
Domain/
question
Adequate
sequence
generation?
Allocation
concealment
used? Blinding?
Concurrent
therapies
similar?
Incomplete
outcome data
addressed?
Uniform and
explicit
outcome
definitions?
Free of
selective
outcome
reporting?
Free of
other
bias?
Overall
risk
of bias?
Abdel-Rahman
et al, 2005
Unclear Unclear No Yes No No No Yes Moderate
Beghi et al, 2006 Unclear Yes No Yes No No No Yes Moderate
Castiglioni et al,
2007
Unclear Yes No Yes No No No Yes Moderate
Fromes et al, 2002 Unclear Yes No Yes No No No Yes Moderate
Huybregts et al,
2007
Unclear Unclear No Yes No No No Yes Moderate
Kamiya et al, 2006 Unclear Unclear No Yes No No No Yes Moderate
Kutschka et al,
2007
Unclear Unclear No Yes No No No Yes Moderate
Mazzei et al, 2007 Unclear Unclear No Yes No No No Yes Moderate
Ohata et al, 2007 Unclear Unclear No Yes No No No Yes Moderate
Prasser et al, 2007 Yes
(computer-
generated
random
numbers)
Unclear No Yes No No No Yes Moderate
Remadi et al, 2004
(I)
Unclear Unclear No Yes No No No Yes Moderate
Remadi et al, 2006
(II)
Unclear Unclear No Yes No No No Yes Moderate
Scho¨ttler et al,
2008
Unclear Unclear No Yes No No No Yes Moderate
Skrabal et al, 2007 Unclear Unclear No Yes No No No Yes Moderate
Valtonen et al,
2007
Unclear Unclear No Yes No No No Yes Moderate
Wippermann et al,
2005
Unclear Unclear No Yes No No No Yes Moderate
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C
DStudy quality appraisal showed that most studies ap-
peared of suboptimal quality, as testified by the common
lack of details on the method used for randomized sequence
generation and allocation (Table 3).
Quantitative Data Synthesis
Overall analysis showed that, in comparison with standard
cardiac surgery,miniaturizedCPBwas associatedwith signif-
icant reductions in the rates of the major end points.
Specifically,miniaturizedCPB reduced the risk of transfusion
(55/552 [9.9%] patients were transfused in the miniaturized
CPB group vs 101/563 [17.9%] in the control arm, OR ¼
0.42 [0.28–0.63], P for effect< .001, P for heterogeneity ¼
.58, I2 ¼ 0%; Figure 2), reduced neurologic damage (4/548
[0.7%] vs 19/555 [3.4%], OR ¼ 0.30 [0.12–0.73], P for ef-
fect ¼ .008, P for heterogeneity ¼ .78, I2 ¼ 0%; Figure 3).
UseofminiaturizedCPBwasalsoassociatedwitha significant
reduction in peak cardiac troponin I release (ng/dL; WMD
1.83 [2.47;1.20], P for effect<.001, P for heterogeneity
< .001, I2 ¼ 97.4% with 760 included patients; Figure 4)
and reduced blood loss (mL; WMD ¼ 83.20The Journal of Thoracic and Car[124.46;41.94], P for effect< .0001, P for heterogeneity
¼ .001, I2 ¼ 69.1% with 1083 included patients; Figure 5).
No effect was noted with intensive care unit stay (WMD
¼3.18 hours [6.96;0.61], P for effect¼ .10, P for hetero-
geneity< .001, I2 ¼ 96.9% with 1400 included patients),
time to hospital discharge (WMD ¼ 0.11 days
[0.42;0.21], P for effect ¼ .50, P for heterogeneity<
.33, I2 ¼ 13.6% with 1130 included patients), time on me-
chanical ventilation (WMD ¼0.49 hours [1.18; 0.20], P
for effect ¼ .16, P for heterogeneity .33, I2 ¼ 12.8% with
913 included patients), need for inotropic support (82/628
[13.0%] vs 87/642 [13.5%], OR ¼ 0.91 [0.61, 1.36], P
for effect ¼ .63, P for heterogeneity ¼ .15, I2 ¼ 34.6%
with 1270 included patients), atrial fibrillation (89/297
[30%] vs 104/303 [34.3%], OR ¼ 0.83 [0.59, 1.17], P for
effect ¼ .28, P for heterogeneity ¼ .69, I2 ¼ 0% with 600
included patients), low cardiac output syndrome (5/400
[1.2%] vs 13/406 [3.2%], OR ¼ 0.38 [0.14, 1.08], P for ef-
fect ¼ .07, P for heterogeneity ¼ .17, I2 ¼ 43.7% with 806
included patients), intra-aortic balloon pump (3/447 [0.6%]
vs 3/459 [0.6%], OR¼ 1.03 [0.23, 4.56], P for effect¼ .97,diovascular Surgery c Volume 139, Number 5 1165
629 citations retrieved
from database searches 
604 from PubMed
25 additional hits
22 studies assessed according
to the selection criteria 
16 Randomized Controlled Trials
finally included
in the systematic review  
607 titles/abstracts excluded
because non-relevant
6 studies excluded according to
explicit exclusion criteria 
FIGURE 1. Flow diagram of the systematic review process.
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DP for heterogeneity ¼ .41, I2 ¼ 0% with 906 included pa-
tients), surgical reexploration for bleeding (12/358 [3.3%]
vs 8/372 [2.1%], OR ¼ 1.52 [0.64, 3.59], P for effect ¼
.34, P for heterogeneity ¼ .81, I2 ¼ 0% with 730 included
patients), myocardial infarction (1/233 [0.4%] vs 3/240
[1.25%], OR ¼ 0.55 [0.12, 2.62], P for effect ¼ .45, P for
heterogeneity ¼ .43, I2 ¼ 0% with 473 included patients),
and mortality (8/758 [1.0%] vs 14/771 [1.8%], OR ¼
0.60 [0.26, 1.39], P for effect ¼ .23, P for heterogeneity ¼
.97, I2 ¼ 0%).
We also appraised the robustness and validity of our find-
ings by exploring the likelihood of small-study bias by
means of funnel plot inspection, finding no major evidenceFIGURE 2. Forest plot for the risk of red blood cell transfusions comparing min
df, degrees of freedom; OR, odds ratio pooled estimates of red blood cell transf
1166 The Journal of Thoracic and Cardiovascular Surof such bias. We repeated the analysis excluding the only
study where the comparator was off-pump CABG, confirm-
ing the results of the major analysis. We also repeated the
analysis excluding the Remadi II study27 that accounted
for 400 of 1619 overall patients and found no differences
in the results with exception of the incidence of reduced neu-
rologic damage (3/348 vs 12/355, OR¼ 0.38 [0.14–1.02], P
¼ .06), which lost statistical significance.DISCUSSION
We performed a meta-analysis of pooled data from sev-
eral small, underpowered studies and demonstrated that min-
iaturized CPB significantly decreases blood loss, rate of
transfusion, and myocardial and neurologic damage. This
technology does not add any benefit in terms of reduction
of mortality.
Miniaturized CPB is a new concept of CPB that is based
on previous research on reduction of hemodilution,32-36
coated systems,37 avoidance of cardiotomy suction,38 and
blood–air contact.39 Cardiac surgery and CPB trigger a sys-
temic inflammatory reaction largely caused by the contact of
blood with foreign surfaces and by recirculation of activated
shed mediastinal blood, which is the main trigger of blood
cell activation and cytokine release.40 Miniaturized CPB is
a closed circuit and involves little or no blood–air contact.
It also combines a coating, which may decrease thrombin
generation and inflammation, and a low priming volume,
which contributes to less hemodilution.
Miniaturized CPB was developed to significantly reduce
the hemodilution of the patient and the foreign surface
area that comes in contact with the patient’s blood. Blood–
material interactions are optimized by the use of tip-to-tip
coating, centrifugal pumps, and membrane oxygenators;
blood–air interaction is avoided by eliminating the venousiaturized cardiopulmonary bypass versus control. CI, Confidence intervals;
usions.
gery c May 2010
FIGURE 3. Forest plot for the risk of neurologic events comparing miniaturized cardiopulmonary bypass versus control. CI, Confidence intervals; df, de-
grees of freedom; OR, odds ratio pooled estimates of neurologic events.
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Dreservoir and cardiotomy suction. Not adding blood from the
pericardial wound directly to the perfusion circuit may sub-
stantially reduce the amount of circulating thrombin and the
severity of the consumptive coagulopathy associated with
CPB. Taking these peculiarities into account, the positive re-
sults in terms of reduction of postoperative bleeding and
need for transfusions are easily explained.
The mechanisms supporting the reduction of myocardial
injury with miniaturized CPB in terms of reduction of car-
diac troponin release deserve some speculation: it is possible
that the unavoidable loss of myocardial cells inherent in aor-
tic crossclamping might be blunted by miniaturized CPB, as
a result of reduced production of interleukins and cytokines.
This is extremely difficult to determine as probably the most
important determinant for the ultimate clinical outcome is
the balance between pro- and anti-inflammatory mediators.
It is also fair to acknowledge that our meta-analysis failedFIGURE 4. Forest plot for postoperative peak troponin release (ng/mL) compa
dom; OR, odds ratio pooled estimates of postoperative peak troponin release.
The Journal of Thoracic and Carto show any translation of these data into clinically relevant
end point (myocardial infarction, need for inotropic support
and intra-aortic balloon pump, low output syndrome).
The data on the better neurologic outcome are strikingly
interesting as amajor drawback ofminiaturizedCPB systems
(for the lack of venous reservoir and arterial filter) is the po-
tential entrapment of air with the risk of cerebral embolism.
Again, these data confirm, in our opinion, that postbypass
brain injury is the result of an interplay between micro- and
macroemboli, cerebral blood flow, and the inflammatory re-
sponse. It would actually be unfair to blame standardCPB for
inducing neurologic damage; it should be emphasized, how-
ever, that the mitigation of the inflammatory response by
miniaturized CPB might transfer into relevant clinical out-
comes. Indeed, Mazzei and colleagues23 claim that miniatur-
ized CPB achieves a degree of brain protection that is
comparable to that attributed to off-pump procedures.ring mini CPB versus control. CI, Confidence intervals; df, degrees of free-
diovascular Surgery c Volume 139, Number 5 1167
FIGURE 5. Forest plot for blood loss (mL) comparing miniaturized cardiopulmonary bypass versus control. CI, Confidence intervals; df, degrees of free-
dom; OR, odds ratio pooled estimates of blood loss mortality.
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DNegative findings also have to be acknowledged: Scho¨t-
tler and associates28 reported negative hemodynamic effects
with more frequent dependence on norepinephrine after op-
erations using miniaturized CPB.
Apart from the operative and in-hospital results, the wide-
spreadapplication ofminiaturizedCPBsystems is jeopardized
by the lack of outcome data. The long-term results are too in-
frequently reported in the current literature to draw definitive
conclusions; of particular concern is graft patency, which has
already contributed to the disappointing evaluation of off-
pumpCABG, despite the positivefindings in the perioperative
period.41 Mazzei and coworkers23 evaluated their study pop-
ulation at 1-year follow-up in terms ofmortality, angina recur-
rence, and need for revascularization: there was a trend in
favor of miniaturized CPB as compared with off-pump
CABG, but no statistically significant data.
Limitations
A critical and balanced review of the literature on minia-
turized CPB, through this meta-analysis, does not allow us to
draw an unequivocal answer on the role of this technique.
This is primarily due to methodologic concerns: small num-
ber of high-risk patients, surrogate end points, confounding
factors (different miniaturized CPB systems, anticoagulation
management, cardioplegia).
An exact comparison of previously published results is
difficult because of varying methodologies. Different mini-
aturized CPB systems and cardioplegic solutions were
used. Despite imbalances between treatment strategies
among different studies, randomized allocation is main-
tained by our meta-analysis, limiting the impact of such im-
balances. The control group also included 1 off-pump series,
ultimately mixing another variable. Even if by far the results
of this meta-analysis outweigh the issue of cost and any ben-
eficial effect in term of transfusion injury and cardiac and
neurologic damage should be rewarded, we acknowledge1168 The Journal of Thoracic and Cardiovascular Surthat no cost analysis was performed among the included
studies. Most study groups received the same CPB coating,
whereas others (n¼ 5) had different surface coating. The au-
thors are aware that this is a methodologic limitation; never-
theless, data on surface coating are not so strong enough in
standard CPB to jeopardize the results of the present meta-
analysis. Furthermore, the total surface area of these circuits
was often not reported by the studies included in the meta-
analysis.Conclusions
Our meta-analysis confirms the potential benefits of dif-
ferent miniaturized CPB systems in comparison to standard
cardiac surgery in terms of decreased transfusion rate and
cardiac and neurologic damage. The strong interest in min-
iaturized CPB might be accounted for the expected reduc-
tions in mortality in subgroups of patients who may
greatly benefit from miniaturized CPB (patients with severe
extracardiac comorbidities, advanced left ventricular dys-
function); new, large randomized controlled trials will clar-
ify this intriguing aspect.References
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